Post-translational control (PTC) Therapeutics was founded in South Plainfield, New Jersey in 1998 by Dr. Stuart Peltz.  On June 30, 2017, PTC Therapeutics, Inc. had $133,011 in cash and cash equivalents.  As of October 30th, 2017 the total equity for PTC Therapeutics was .  For 2013, PTC Therapeutics had $ million in collaboration revenue.  In 2017, PTC Therapeutics, Inc. was authorized in the European Union to have provisional marketing authorization of the lead product candidate Translarna.  Translarna is used to treat nonsense mutation of Duchenne muscular dystrophy. PTC Therapeutics, Inc. filed for an extension of the trademark PTC Therapeutics on December 17, 2015.  PTC Therapeutics has 16 other trade marks including Translarna, Aperluri, Ilumerna, EmflazaCares, Emflaza, Kynzetix, Aldondis, Eurpizd, Aperluri, Ilumerna, and PTC124.  In 2017, PTC Therapeutics was covered by Bank of America, Barclays, Citi, Cowen and Company, Credit Suisse, . Morgan Securities, RBC, and William Blair. 
Hi poor you. I only stayed on steroids for three months, and I manage by taking diclofenac sodium. It's a slow release medication and I take 75mg a day. If I miss a day the symptons start coming back after about 28 hours. This doesn't make me completely pain free, but my rheumy and I are happy that I can cope with some pain and not get myself traumatised by the steroids again. There are of course side effects if I take it long term (already been on it since end Feb) but they're not in the same league as steroid side effects.
Mercier et al. (2013) reviewed the features of 26 female carriers of pathogenic mutations in the DMD gene who were referred for symptoms related to the disorder before 17 years of age. Five had a Duchenne-like phenotype with loss of ambulation before age 15 years, 13 had a Becker-like phenotype with muscle weakness but persistence of ambulation after age 15 years, and 8 had exercise intolerance. Initial symptoms included significant muscle weakness (88%), mostly affecting the lower limbs, or exercise intolerance (27%). Cardiac dysfunction was present in 19%, and cognitive impairment in 27%. Cognitive impairment was associated with mutations in the distal part of the gene. Muscle biopsy showed dystrophic changes in 83% and mosaic immunostaining for dystrophin in 81%. The X-chromosome inactivation pattern was biased in 62% of cases. Mercier et al. (2013) concluded that carrier females may have significant symptoms of the disorder.